Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV

The goal of this clinical trial is to learn whether it is possible to use intramuscular (IM) ketamine in combination with psychotherapy to treat moderate-to-severe methamphetamine use disorder (MeUD) in publicly insured patients with or at-risk for HIV disease. The main questions it aims to answer are: * Do publicly insured patients find ketamine-assisted psychotherapy feasible and acceptable as a potential treatment for MeUD? * Is IM ketamine safe and tolerable among patients with MeUD? Participants will: * Receive 3 monitored doses of IM ketamine * Have 3 preparation and 4 integration psychotherapy visits * Report their daily amounts of methamphetamine used prior to, during, and up to 3 months following the intervention

NCT Number	NCT06538285
Lead Sponsor	Nicky Mehtani, MD, MPH Collaborators: San Francisco Department of Public Health, California HIV/AIDS Research Program, National Center for Advancing Translational Sciences (NCATS)
Conditions	Methamphetamine Use Disorder
Enrollment	17 participants
Start Date	2025-03-04
Primary Completion	2026-05-05 (estimated)
Study Completion	2026-06-14 (estimated)
Updated on ClinicalTrials.gov	2026-08-12